Protective effects of probucol in two animal models of atherosclerosis.
Lau
A K
AK
Biochemistry Group, The Heart Research Institute, Sydney, New South Wales, Australia.
Witting
P K
PK
Chaufour
X
X
Celermajer
D S
DS
Pettersson
K
K
Stocker
R
R
D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001012:Aorta, Abdominal / Q000187:drug effects / Q000473:pathology; D001013:Aorta, Thoracic / Q000187:drug effects / Q000473:pathology; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics*; D001161:Arteriosclerosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D002791:Cholesterol, Dietary; D004036:Diet, Atherogenic; D004041:Dietary Fats; D004195:Disease Models, Animal; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011341:Probucol / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D001057:Apolipoproteins E; D002791:Cholesterol, Dietary; D004041:Dietary Fats; D011341:Probucol